Shahid Mansoor, MD
Nephrology · Yuma, AZNPI 1053301747
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $464 of the $545 with a category attached, or 85.2%. It is spread thinly across 17 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $167 and has fallen 85.9% since, to $23 in 2025. That places this record below the midpoint for nephrology clinicians in AZ, where the typical reported total is $2,217.
Across 30 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$126
- Novo Nordisk$65
- GSK$47
- Medtronic$44
- Akebia Therapeutics Inc$32
- Fresenius USA Marketing, Inc.$31
- plus $200 from 11 others
What the payments were for
- Speaking & faculty fees$112%
- Food & beverage$46485%
- Education$7013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $126 |
| Novo Nordisk | 4 | $65 |
| GSK | 2 | $47 |
| Medtronic | 3 | $44 |
| Akebia Therapeutics Inc | 2 | $32 |
| Fresenius USA Marketing, Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Lilly USA, LLC | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Sanofi | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Abbott | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Acorda Therapeutics, Inc | 1 | $11 |
How this compares
$545 in reported general payments places this provider in the 25th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 14 | $479 |
| Amlodipine Besylate | 25 | $191 |
| Losartan Potassium | 17 | $178 |
| Furosemide | 22 | $152 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Yuma
- Claudia VelardeYuma$8K
- Kamal Eldin AhmedYuma$6K
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
- Samer Bani HaniPhoenix$54K
- Aneesha ShettyTucson$34K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.